Application
Increasing emergence of antibiotic-resistant strains of staphylococci in the human and veterinary medicine marketplace hampers chemotherapeutic treatments of these infections.
Amid the novel coronavirus pandemic and beyond, the ImmLab human vaccine can be used in a protective anti-staphylococcal manner while also delivering significant benefits of specific and non-specific immunity boost needed for vulnerable populations.
Our Technology
ImmLab staphylococcal vaccines are created by introducing the genome of the staphylococcal bacteriophage into the staphylococcal cell, resulting in the production of highly immunogenic vaccine comprised of all staphylococcal proteins and cell-wall components.
This approach induces several innate and adaptive immune responses through multiple mechanisms.
Based on 40+ years of research, ImmLab has developed novel technological inventions for the prevention and treatment of staphylococcal infections in humans and animals.
With our patented technology, ImmLab is further able to develop new products in reaction to actual epidemiological situations resulting from emerging, resistant bacterial strains.
Stable, tested and effective staphylococcal vaccines
Immunology Laboratories, Inc.
Our Products
ImmLab’s product line of staphylococcal-lysate-based vaccines for prevention and treatment of staphylococcal infections in humans, companion animals, and farm animals not only improves the health and well-being of those subject to microbial infections but does so using an approach that will not add to the growing threat of antibiotic-resistant bacterial strains and super-pathogens.